Direct Detection of Circulating Donor-Derived Extracellular Vesicles in Kidney Transplant Recipients 6 161 Control Other Diagnosis Presumed Rejection Rejection p-test n = 11 3 5 7 Recipient Age (Years) 58.64 (10.06) 62.33 (10.21) 61.20 (14.55) 58.29 (16.43) 0.95 Recipient Gender (Male) 9 (81.8) 3 (100.0) 1 (20.0) 3 (42.9) 0.04 Recipient BMI 27.45 (5.13) 28.03 (11.94) 26.62 (2.27) 27.44 (4.92) 0.99 Donor Type 0.60 DBD 3 (27.3) 1 (33.3) 0 (0.0) 3 (42.9) DCD 3 (27.3) 2 (66.7) 1 (20.0) 2 (28.6) Living Donor - Related 1 (9.1) 0 (0.0) 1 (20.0) 0 (0.0) Living Donor - Unrelated 4 (36.4) 0 (0.0) 3 (60.0) 2 (28.6) Donor Age (Years) 54.09 (17.68) 66.00 (2.65) 61.20 (13.55) 64.00 (6.90) 0.38 Donor Gender (Male) 4 (36.4) 1 (33.3) 4 (80.0) 3 (42.9) 0.40 Missmatch HLA-A 0.217 0 0 (0.0) 0 (0.0) 1 (20.0) 0 (0.0) 1 9 (81.8) 2 (66.7) 1 (20.0) 4 (57.1) 2 2 (18.2) 1 (33.3) 3 (60.0) 3 (42.9) Missmatch HLA-B 0.56 0 2 (18.2) 0 (0.0) 0 (0.0) 0 (0.0) 1 4 (36.4) 1 (33.3) 1 (20.0) 4 (57.1) 2 5 (45.5) 2 (66.7) 4 (80.0) 3 (42.9) Missmatch HLA-DR 0.02 0 4 (36.4) 0 (0.0) 0 (0.0) 3 (42.9) 1 5 (45.5) 0 (0.0) 5 (100.0) 2 (28.6) 2 2 (18.2) 3 (100.0) 0 (0.0) 2 (28.6) Induction Therapy Basiliximab 11 (100.0) 3 (100.0) 5 (100.0) 5 (71.4) 0.12 Alemtuzumab 0 (0.0) 0 (0.0) 0 (0.0) 2 (28.6) 0.12 Maintenance Immunosuppression TAC / MMF / Prednisolone 11 (100.0) 3 (100.0) 5 (100.0) 7 (100.0) NA Table 1 – Patient characteristics corresponding to the samples included in our analysis after exclusion of samples not passing the 95% reduction after detergent treatment. For the dd-EV analysis, samples from a total of 26 KTRs were included in the analysis (Figure 4B). Continued variables are described as mean (SD). Categorical variables as number of cases (%). ATG, antithymocyte globulin; BMI, body mass index; DBD, donation after brain death; DCD, donation after circulatory death; MMF, mycophenolate mofetil; MPA, Mycophenolic Acid; TAC, tacrolimus.
RkJQdWJsaXNoZXIy MTk4NDMw